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Objectives
In 2011, a consensus was reached defining “late presenters” (LPs) as individuals presenting for
care with a CD4 count < 350 cells/μL or with an AIDS-defining event, regardless of CD4 count.
However, a transient low CD4 count is not uncommon in recent infections. The objective of this
study was to investigate how measurements of late presentation change if the clinical stage at
the time of diagnosis is taken into account.
Methods
Case surveillance data for newly diagnosed patients in Belgium in 1998–2012 were analysed,
including CD4 count at diagnosis, the presence of AIDS-defining events, and recent infections
(< 6 months) as reported by clinicians in the case of acute illness or a recent negative test. First,
proportions of LPs were calculated according to the consensus definition. Secondly, LPs were
reclassified as “nonlate” if infections were reported as recent.
Results
A total of 7949 HIV diagnoses were included in the study. Recent infections were increasingly
reported over time, accounting for 8.2% of new infections in 1998 and 37.5% in 2012. The
consideration of clinical stage significantly modified the proportion of LPs: 18.2% of men who
have sex with men (MSM) diagnosed in 2012 would be classified as LPs instead of 30.9% using
the consensus definition (P < 0.001). The proportion of patients misclassified as LPs increased
significantly over time: 5% in MSM in 1998 vs. 41% in 2012.
Conclusions
This study suggests that low CD4 counts in recent infections may lead to overestimation of late
presentation when applying the consensus definition. The impact of transient CD4 count on late
presentation estimates should be assessed and, if relevant, the introduction of clinical stage in
the definition of late presentation should be considered.
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Introduction
In 2011, a consensus was reached defining “late presenters”
(LPs) as individuals presenting for care with a CD4 count
< 350 cells/μL or presenting with an AIDS-defining event,
regardless of CD4 count [1]. This consensus definition is
broadly used in HIV surveillance to evaluate the prevalence
and determinants of late presentation [2–4] and to assess
the effectiveness of testing campaigns. At the European
level, 47% of those diagnosed with HIV infection
where information is available on CD4 count have a low
count, < 350 cells/μL, at the time of diagnosis [5]. In
Belgium, despite progress over the last 15 years, a consid-
erable proportion (42%) of HIV diagnoses with information
on CD4 count are still made “at a late stage” when the CD4
count has dropped below 350 cells/μL or when AIDS is
diagnosed. In 2012, 31% of men who have sex with men
(MSM) and 51% of heterosexuals diagnosed with HIV
infection were classified as being diagnosed late.
However, looking only at CD4 count may lead to
misclassification of late presentation. It has been shown
that a transient low CD4 count is not uncommon in recent
infections [6] and that early low CD4 counts may be pre-
dictive of fast disease progression [7]. Low CD4 counts
during seroconversion were observed in various studies.
The upper limit of the first quartile of the CD4 count was at
342 cells/μL in the CASCADE (Concerted Action on
SeroConversion to AIDS and Death in Europe) cohort study,
which included patients diagnosed within 6 months after
seroconversion [7–9]. In a Brazilian study, the median CD4
count at presentation was 373 cells/μL [10]. In these
cohorts, a significant proportion of patients in seroconver-
sion (25 to 50%) would therefore have been considered as
LPs according to the classical definition.
Late presentation is an essential indicator used to assess
the effectiveness of prevention programmes and testing
campaigns. This study aimed to determine how measure-
ments of late presentation change when the clinical stage
at the time of diagnosis is taken into account in order to
elucidate how to more accurately interpret early CD4 cell
counts and estimate the proportion of delayed diagnoses.
Methods
Case surveillance data for patients newly diagnosed with
HIV infection in Belgium from 1998 to 2012 were analysed.
These data included CD4 count at diagnosis, the presence
of AIDS-defining events and whether or not the HIV infec-
tion was considered as recent by the clinician. The criteria
for a recent infection (< 6 months) included a recent nega-
tive test, a typical clinical presentation of acute infection
and a history of recent risk behaviour with a known HIV-
positive partner. CD4 cell count data were available for
51% of the new diagnoses; the clinical stage was reported
by clinicians for 67% of new diagnoses. First, proportions
of LPs were calculated according to the classical definition
using a CD4 count < 350 cells/μL or presentation with an
AIDS-defining event. Secondly, LPs were reclassified as
“nonlate” if a recent infection was reported by clinicians.
The reclassification was quantified and associated factors
were identified using logistic regression.
Results
A total of 7949 HIV-diagnosed individuals were included
in the analysis, of whom 38.4% were Belgians, 43.2%
sub-Saharan Africans, 10.3% other Europeans and 8.2%
of other nationalities. Sixty-four per cent of individuals
included were male, 54.4% were heterosexuals and 33.8%
were MSM. The yearly number of new diagnoses reported
as recent HIV infections increased by 700% between 1998
and 2012, accounting for 8.2% of new infections in 1998
and 37.5% in 2012. (Fig. 1). Among MSM, the proportion
of infections reported as recent rose sharply and consist-
ently, 56.3% of HIV diagnoses among MSM being recent
infections in 2012. In contrast, the proportion of recent
HIV infections in heterosexuals remained stable over the
past decade, only 23.6% being reported as recent in 2012.
Among individuals with infections reported as recent,
the median CD4 count was 457 cells/μL; 31.8% had a CD4
count < 350 cells/μL, which is close to the proportion
observed in other cohorts of seroconverters [7–10].
Furthermore, CD4 counts < 200 cells/μL were reported in
12.9% of recent infections.
A significant proportion of LPs according to the con-
sensus definition were reclassified as non-LPs when the
clinical stage was taken into account. For the year 2012,
only 33% of the new cases would have been considered
as LPs instead of 42.4%. Among MSM, 18.2% of patients
would have been considered as LPs instead of 30.9%
(P < 0.001) (Fig. 2a). Among heterosexuals, the reclassifi-
cation resulted in a limited and nonsignificant change in
the percentage of LPs, from 51.3% to 44.5% for the year
2012 (Fig. 2b).
The reclassification was independently associated with
younger age at diagnosis (P < 0.05), sex between men
(P < 0.001), Belgian or other European nationality
(P < 0.01) and later calendar year of diagnosis (P < 0.001).
The strong association with year of diagnosis is reflected in
an increasing proportion over time of patients falsely clas-
sified as LPs: among MSM, 5% of LPs were reclassified as
non-LPs in 1998 vs. 41% in 2012, meaning that the speci-
ficity of the classical definition of late presentation may
have decreased over time.
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Discussion
This study shows that taking into account the clinical stage
at diagnosis significantly modifies the late presentation
status assigned using the consensus definition and that the
consensus definition for late presentation based only on
CD4 count can overestimate the number of LPs. By exclud-
ing those with recent infections presenting a transient or
early low CD4 count, this study aimed to more accurately
identify patients whose diagnosis was delayed in time,
whereas the consensus definition will rather identify
patients presenting late from the point of view of evolving
disease and its therapeutic implications.
This study has some limitations. First, we used routine
surveillance data for all diagnosed HIV infections reported
during a 15-year period and, despite increasing compre-
hensiveness, a large proportion of CD4 count data at diag-
nosis are still missing in recent years (41% in 2013), which
is slightly higher than the European Union (EU) average of
39% in 2013 [5]. This highlights the need to focus on
improving epidemiological data collection to improve the
completeness of CD4 count at diagnosis as well as data on
clinical stage. Secondly, the validity of information on the
recentness of the infection collected by the clinicians may
be subject to subjectivity and recall bias. The validity of the
criterion “recent risk behaviour with a known HIV-positive
partner”, which was not collected and analysed separately,
may also be discussed. Nevertheless, the CD4 count distri-
bution observed among the recent infections was compa-
rable with what has been reported in other studies [7–10].
Thirdly, specific tests for incidence analysis [enzyme-linked
immunosorbent assays (ELISAs) measuring antibody con-
centration or avidity] were not performed and results of
other laboratory analyses to document the infection stage,
Fig. 1 Clinical stage at HIV diagnosis in Belgium, in 1998–2012, in (a) men who have sex with men and (b) heterosexuals.
Fig. 2 Reclassification of late presentation according to clinical stage in (a) men who have sex with men and (b) heterosexuals.
Late presentation to HIV testing is overestimated when based on the consensus definition 3
© 2015 Scientific Institute Public Health. HIV Medicine published by
John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2015)
for example using the Fiebig classification [11], were not
available. Nor was analysis of subsequent CD4 counts
possible because of the absence of data on antiviral treat-
ment history.
The study shows a significant increase in recent infec-
tions among new diagnoses over the years, especially
among MSM [12]; this trend may result from the screening
campaigns implemented during the last decade. Taking into
account the clinical stage data resulted in lower late pres-
entation estimates. Nevertheless, even when corrected, late
presentation levels remained too high. Late presentation to
HIV testing and delays throughout the continuum of care
have major consequences: increased morbidity and mor-
tality, increased health costs, and increased opportunities
for ongoing HIV transmission. The data provide strong
support for campaigns to encourage early infection diag-
nosis and testing. The need for such campaigns was
emphasized in the Belgian National HIV plan launched in
October 2013 [13].
Late presentation is an essential indicator for monitoring
prevention programmes, assessing the effectiveness of
testing campaigns and allocating resources. This first study
suggests that the possible drop in CD4 count in recent
infections may lead to overestimation of late presentation
when the common definition is applied, and that a propor-
tion of LPs are possibly very early presenters, especially
among MSM.
The presence of low and very low CD4 counts during the
early phase of infection should be better known and quan-
tified, and the impact of transient low CD4 counts and
early low CD4 counts on LP estimates should be assessed.
If relevant, the inclusion of clinical stage in the definition
of late presentation should be considered in order to
increase the specificity of the definition and provide a more
reliable estimate of the proportion of delayed diagnoses.
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